Following the GAO’s investigation into US government IP licensing, BIO’s IP head Hans Sauer talks of his worries about a shift in federal patent strategy and explains why public research funding should not be seen as a commercial investment
Following the GAO’s investigation into US government IP licensing, BIO’s IP head Hans Sauer talks of his worries about a shift in federal patent strategy and explains why public research funding should not be seen as a commercial investment